Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.46 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.42 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL655129 | 0.84 | ADORA3 (0.56) | PI4KBKCNH2ADORA3ADORA2AADORA1 | |
| SCHEMBL653091 | 0.80 | CYP3A4 (0.46) | SMN1; SMN2KDM4ECYP3A4PI4KBKCNH2 | |
| SCHEMBL653630 | 0.77 | PI4KB (0.60) | KDM4ECYP3A4PI4KBKCNH2CYP1A2 | |
| SCHEMBL656083 | 0.75 | IKBKB (0.49) | RAB9AALOX5ADORA3ADORA2AADORA1 | |
| SCHEMBL654509 | 0.75 | ADORA3 (0.45) | SMN1; SMN2KDM4ERAB9ANPC1ALOX5 | |
| SCHEMBL654078 | 0.75 | ADORA2A (0.58) | SMN1; SMN2KDM4ERAB9ALMNAADORA3 | |
| SCHEMBL655584 | 0.72 | KDM4E (0.47) | SMN1; SMN2KDM4ECYP3A4RAB9ANPC1 | |
| SCHEMBL16650147 | 0.71 | PI4KB (0.71) | CYP3A4PI4KBKCNH2ALOX5CYP2C19 | |
| SCHEMBL659393 | 0.70 | ADORA2A (0.60) | ADORA3ADORA2AADORA1 | |
| SCHEMBL17803423 | 0.70 | NPC1 (0.55) | SMN1; SMN2KDM4ECYP3A4PI4KBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9730944-B2 | Antiviral activity of novel bicyclic heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2017-08-15 | — | — | US | disclosed |
| US-9573966-B2 | Anti-cancer activity of novel bicyclic heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2017-02-21 | — | — | US | disclosed |
| EP-2616077-B1 | ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | UNIV LEUVEN KATH (BE) | 2016-08-31 | — | — | EP | disclosed |
| US-20160030447-A1 | Antiviral Activity of Novel Bicyclic Heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2016-02-04 | — | — | US | disclosed |
| US-9221822-B2 | Thiazolopyrimidine modulators as immunosuppressive agents | KATHOLIEKE UNIVERSITEIT LEUVEN, K. U. LEUVEN R&D (BE) | 2015-12-29 | — | — | US | disclosed |
| US-9193741-B2 | Antiviral activity of bicyclic heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K. U. LEUVEN R&D (BE) | 2015-11-24 | — | — | US | disclosed |
| EP-2923734-A1 | Purine analogues and their use as immunosuppressive agents | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2015-09-30 | — | — | EP | disclosed |
| EP-2405973-B1 | THIAZOLOPYRIMIDINE MODULATORS AS IMMUNOSUPPRESSIVE AGENTS | UNIV LEUVEN KATH (BE) | 2015-04-22 | — | — | EP | disclosed |
| US-20150038494-A1 | Thiazolopyrimidine Modulators as Immunosuppressive Agents | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2015-02-05 | — | — | US | disclosed |
| US-8901132-B2 | Thiazolopyrimidine modulators as immunosuppressive agents | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2014-12-02 | — | — | US | disclosed |
| US-20140088088-A1 | ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2014-03-27 | — | — | US | disclosed |
| US-20130190297-A1 | Antiviral Activity of Novel Bicyclic Heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2013-07-25 | — | — | US | disclosed |
| EP-2616077-A1 | ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2013-07-24 | — | — | EP | disclosed |
| EP-2575969-A1 | ANTIVIRAL ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2013-04-10 | — | — | EP | disclosed |
| WO-2012035423-A1 | ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2012-03-22 | — | — | WO | disclosed |
| US-20120046278-A1 | THIAZOLOPYRIMIDINE MODULATORS AS IMMUNOSUPPRESSIVE AGENTS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2012-02-23 | — | — | US | disclosed |
| EP-2405973-A2 | THIAZOLOPYRIMIDINE MODULATORS AS IMMUNOSUPPRESSIVE AGENTS | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2012-01-18 | — | — | EP | disclosed |
| WO-2011147753-A1 | ANTIVIRAL ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2011-12-01 | — | — | WO | disclosed |
| WO-2010103130-A2 | NOVEL BICYCLIC HETEROCYCLES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038494-A1 | Thiazolopyrimidine Modulators as Immunosuppressive Agents | TPMT, STAT6, IL4 | SMN1; SMN2 4474/4885KDM4E 1646/4885CYP3A4 397/4885 |
| US-20120046278-A1 | THIAZOLOPYRIMIDINE MODULATORS AS IMMUNOSUPPRESSIVE AGENTS | TPMT, STAT6, IL4 | SMN1; SMN2 4474/4885KDM4E 1646/4885CYP3A4 397/4885 |
| US-20130190297-A1 | Antiviral Activity of Novel Bicyclic Heterocycles | HAVCR2, RNASE1, RNASEH1 | SMN1; SMN2 662/4885KDM4E 3714/4885CYP3A4 268/4885 |
| US-20140088088-A1 | ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | CCNA1, CCND3, CCND1 | SMN1; SMN2 2484/4885KDM4E 1541/4885CYP3A4 1713/4885 |
| US-20160030447-A1 | Antiviral Activity of Novel Bicyclic Heterocycles | RNASE1, HAVCR2, RNASEH1 | SMN1; SMN2 160/4885KDM4E 4332/4885CYP3A4 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.